International journal of Pulmonary & Respiratory Sciences

Mini Review

Diagnostic Criteria for the Asthma-COPD Overlap (ACO) Still Room for Improvement

Alexa Nuñez and Marc Miravitlles*

Department of Pneumology, University Hospital Vall d’ Hebron, Spain

Submission: March 10, 2017; Published: May 31, 2017

*Corresponding author: Marc Miravitlles, Department of Pneumology, University Hospital Vall d’ Hebron, Spain, Email: mmiravitlles@vhebron.net

How to cite this article: Alexa N, Marc M. Diagnostic Criteria for the Asthma-COPD Overlap (ACO) Still Room for Improvement. Int J Pul & Res Sci. 2017; 1(4): 555569. DOI:10.19080/IJOPRS.2017.01.555569

Introduction

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease in which the clinical presentation and prognosis vary according to the phenotype [1]. In the last years, one of the phenotypes of COPD, that is recognized as the Asthma-COPD Overlap (ACO) has received increasing attention.

In contrast with the remaining COPD phenotypes, patients with ACO present an elevated reversibility of airflow obstruction as well as a greater degree of eosinophilic bronchial inflammation, thereby demonstrating greater response to inhaled corticosteroid (ICS) treatment [2-4]. These characteristics are suggestive of asthma and can be explained by a history of asthma during youth being an independent risk factor for the development of COPD in smokers [5] (Figure 1).

From a clinical point of view, patients with ACO present more symptoms, have a worse quality of life and a higher risk of exacerbations than the remaining patients with COPD, but they have a better survival. In the CHAIN study including125 COPD patients labeled as having ACO and who fulfilled specific characteristics associated with asthma according to some diagnostic criteria [major criteria: bronchodilator test (BDR)>400ml and 15%or a history of asthma; minor criteria: eosinophilia >5%, IgE> 100IU/ml or two BDR>200ml and 12 %] were found to have a greater one year survival compared to the remaining patients with COPD without ACO [6].

Likewise, the cohort study by Hokkaido followed 268 patients labeled as having ACO who did not have a previous diagnosis of asthma but fulfilled the characteristics of asthma (reversibility of airflow obstruction ≥12 % and 200 ml, eosinophilia ≥300 eosinophils/μl and/or atopy (specific IgE positive for at least one inhaled antigen), and it was observed that despite these patients presenting a worse score in the St. George quality of life questionnaire, they had a lower mortality at 10 years compared to non ACOS patients probably because of greater response to anti inflammatory treatment with ICS [7].

Globally, the prevalence of ACOS reported varies greatly due to the different diagnostic criteria used. Different epidemiological studies in which ACOS is defined as patients with COPD diagnosed with asthma before the age of 40 described prevalences of 13% and 17% [6,8]. Using the same definition, a multicenter, cross-sectional, observational study carried out in Spain including 3125 patients with COPD in primary care and specialized centers reported a prevalence of ACO of 15.9% [9]. The prevalence of ACO was determined to be between 1.6 and 4.5% in the general adult population and between 15% and 25 % in the adult population with COPD.

In the last years attempts have been made to define the diagnostic criteria of this phenotype, but no definitive consensus has been achieved. In Spain, a diagnostic consensus by the Spanish COPD Guidelines (GesEPOC) was initially proposed, including very restrictive criteria in which 2 major criteria or 1 major and 2 minor criteria had be fulfilled for a patient to be defined as having ACO. The major criteria included a very positiveBDR≥400ml and 15% compared to baseline, eosinophilia in sputum and a personal history of asthma (prior to 40 years of age), and the minor criteria were an elevated total IgE, a history of atopy and a positive BDR ≥200ml and 12% on at least two occasions [10]. Thereafter, an agreement between the Global Initiative for Asthma (GINA) and the Global initiative for Chronic Obstructive Lung Disease (GOLD) defined the ACO phenotype as persistent airflow limitation with characteristics of both asthma and COPD but did not clearly specify how many criteria should be met to establish a diagnosis of ACO [11].

Later in 2016, a consensus was made among specialists in North America, Europe and Asia, proposing 3 major criteria (persistent airflow limitation <0.70 in patients over 40 years of age, exposure to smoking of at least 10 packs-year or the equivalent in biomass smoke exposure, a documented history of asthma before age 40 or BDR>400ml in FEV1) and 3 minor criteria (documented history of atopy or allergic rhinitis, BDR≥200ml and 12%on at least 2 occasions, peripheral eosinopilia ≥300eosinophils/μL). For a diagnosis of ACO, 3 major criteria and at least one of the minor criteria proposed had to be met [12].

More recently, the new consensus between GesEPOC and the Spanish Guidelines for the Management of Asthma (GEMA) defined overlapping of asthma and COPD (ACO) as the presence of chronic persistent airflow limitation, in a smoker or former smoker [tobacco exposure≥10 pack-years] with a concomitant diagnosis of asthma or with characteristics of asthma such as very positive BDR (≥15% and ≥400ml) and/or blood eosinophilia (≥300 eosinpophils/μL). Thus, the ACO phenotype includes not only smoker asthma patients who develop persistent airflow obstruction but also COPD with characteristics of asthma. To fulfill this definition, airflow limitation must be persistent over time, current or past smoking should be the main risk factor, and the patient must present clinical, biological or functional characteristics of asthma [13].

The diagnosis is sequential; the presence of chronic airflow obstruction must first be confirmed with a post bronchodilator FEV1/FVC ratio<0.70 in patients over 35 years of age who are active or former smokers of at least 10 pack-years. In cases of doubtful diagnosis, the patients should undergo spirometry evaluation after at least 6 months of treatment with an ICS and a long-acting β2 agonist (LABA). In case of reversibility of airflow obstruction the diagnosis is asthma. After confirming the persistence of chronic airflow obstruction, the current diagnosis of asthma should be confirmed by a family or personal history or asthma and/or atopy with respiratory symptoms (wheezing, cough, chest oppression) or upper airway inflammation or daily variability of PEF≥20% or exhaled nitric oxide fraction (FENO≥50ppb). If the diagnosis of asthma cannot be established, the diagnosis of ACO is confirmed if a patient with COPD presents features of asthma: a very positive PBD (≥15% and ≥400ml) and/or the presence of eosinophilia in blood (≥300 eosinophils/ μL) [13].

Eosinophilia has shown to be a good biomarker to identify COPD patients showing better response to ICS treatment who fulfill the ACO criteria. However, the cut-off value is controversial. In one study comparing stable COPD patients without ACO with another stable COPD group with ACO, the patients with ACO presented blood eosinophil concentrations double those observed in the COPD group without ACO [14]. Studies comparing eosinophilc inflammation in blood and sputum have suggested that a cut-off value of ≥300eosinophils/μLin blood is a good predictor of eosinophilia in sputum [15]. Different consensuses recommend this cut-off of ≥300 eosinophils/μL in peripheral blood [12,13].

With regard to the treatment of patients fulfilling ACO criteria, the objectives are to prevent exacerbations as well as maintain acceptable control of the symptoms and reduce the grade of bronchial obstruction. The importance of diagnosing ACO is to identify patients with COPD who require treatment with ICS plus LABA from early phases of the disease.

Thus, the new GesEPOC-GEMA consensus establishes a combination of LABA/ICS as the initial treatment. However, a combination of choice cannot be recommended since no study has compared different combinations [13]. Therefore, the elevated doses of ICS currently recommended for the treatment of COPD are associated with a greater incidence of adverse effects, and a dose-response relationship with clinical efficacy has not been demonstrated. Thus, intermediate doses of ICS are recommended for the maintenance of these patients [16].

In more severe cases a long-acting anti cholinergic (LAMA) may be added, constituting triple therapy (LABA/ICS/LAMA). Although in the future some of these patients, particularly the most severe not controlled with triple therapy, may be candidates to treatment with new biological drugs, there are no specific clinical trials on patients with ACO with this particular phenotype.

Likewise, smoking cessation should be insisted upon as should respiratory rehabilitation and the use of nasal anti inflammatories and oxygen therapy in indicated cases [13].